Stellus Rx Acquires Tria Health

The acquisition creates a pharmacist-led platform to support patients throughout their medication journeys.

Apr. 16, 2026 at 5:24pm

A minimalist studio still life photograph featuring a stack of prescription pill bottles, a syringe, and a stethoscope arranged elegantly on a clean, white background, conceptually representing the integration of pharmacist-led patient support and medication management.A new pharmacist-led platform aims to improve medication adherence and reduce healthcare costs for employers, payors, and risk-bearing entities.Plano Today

Stellus Rx, a technology-enabled pharmacy care management platform, has acquired Tria Health, a provider of pharmacist-led chronic condition support for self-insured employers and their members. The combined company aims to improve clinical outcomes, provide more seamless patient experiences, and reduce total cost of care for value-based care organizations, employers, and other risk-bearing stakeholders.

Why it matters

The acquisition brings together two companies with a shared mission of delivering pharmacist-led patient support to improve medication adherence and health outcomes. By combining their expertise, Stellus Rx and Tria Health can expand their impact and unlock greater clinical and economic value than either company could achieve independently.

The details

Stellus Rx, a portfolio company of WindRose Health Investors, will integrate Tria Health's pharmacist-led chronic condition support services into its technology-enabled pharmacy care management platform. The goals are to create a single, pharmacist-led platform that supports patients throughout their medication journeys, improve clinical outcomes, provide more seamless patient experiences, and reduce total cost of care for value-based care organizations, employers, and other risk-bearing stakeholders.

  • The acquisition was announced on April 16, 2026.

The players

Stellus Rx

A technology-enabled pharmacy care management platform and a portfolio company of WindRose Health Investors.

Tria Health

A provider of pharmacist-led chronic condition support for self-insured employers and their members.

Tony Willoughby

CEO of Stellus Rx.

Jessica Lea

CEO of Tria Health.

David Masterman

Principal at WindRose Health Investors.

Got photos? Submit your photos here. ›

What they’re saying

“Too many organizations are leaving value on the table–and, more importantly, patient outcomes suffer–because people don't have the support they need to take the right medications as prescribed. By bringing Stellus Rx and Tria Health together, we're creating a pharmacist‑led platform that helps organizations realize the full clinical and financial impact of effective medication use, across all types of organizations that care about lowering costs through improved health.”

— Tony Willoughby, CEO of Stellus Rx

“Tria Health and Stellus Rx share a deep commitment to patient‑centered, pharmacist‑led support. This marks an exciting next chapter for our team and our clients, allowing us to expand our impact while advancing the care model that has made Tria Health successful.”

— Jessica Lea, CEO of Tria Health

“Stellus Rx and Tria Health combine highly complementary capabilities to support patients and drive more effective medication use. We believe this combination creates a differentiated platform with the ability to deliver meaningful clinical impact while reducing total cost of care for a broad set of stakeholders. We're excited to support the team as they scale this model and expand their reach.”

— David Masterman, Principal at WindRose Health Investors

What’s next

The companies will continue to operate as independent brands in the near term while they work to integrate capabilities and shape the future of pharmacist-led patient support.

The takeaway

The acquisition of Tria Health by Stellus Rx creates a powerful pharmacist-led platform that can improve medication adherence, health outcomes, and reduce healthcare costs for a wide range of stakeholders, including employers, payors, and risk-bearing entities.